NUTX Stock Analysis: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$147.43
-1.28 (-0.86%)
▼
5d:
+1.07%
30d:
-22.69%
90d:
+23.68%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
2d
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NUTX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: NUTX shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$210.64
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$130.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $147.43, which is considered oversold relative to its 30-day fair value range of $151.14 to $183.56. The stock's valuation (Forward PE: 6.4) is in line with its historical norms (7.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.1% over the next few years. This pessimistic expectation contrasts with the company's recent 95.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, NUTX is in a strong uptrend. Immediate support is located at $140.25, while resistance sits at $170.74.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $246.40 (+67.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NUTX is in a strong uptrend. Immediate support is located at $140.25, while resistance sits at $170.74.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $246.40 (+67.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$151.14 -
$183.56
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 67.1% below Wall St target ($246.40)
Trading Range Analysis
30-Day Trading Range
$151.14 -
$183.56
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$140.25
Resistance Level
$170.74
Current Trend
Strong Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.40
Wall Street Target
$246.40
(+67.1%)
Revenue Growth (YoY)
2.2%
Earnings Growth (YoY)
95.9%
Profit Margin
10.9%
Valuation Discount vs History
-3.1% cheaper
PE vs Historical
6.4 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.1%
(market-implied from PE analysis)
1-Year Target
$142.86
(-3%)
2-Year Target
$138.43
(-6%)
3-Year Target
$134.14
(-9%)
3-Yr Target (if PE normalizes)
(PE: 6→7)
$146.68
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 7.0%)
$585.12
(+297%)
Base:
(SPY PE: 6.4, Growth: 7.0%)
$180.69
(+23%)
Bear:
(PE: 5.4, Growth: 7.0%)
$153.59
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 10.88 | Current EPS (TTM): $13.67
Bull Case
$275.59
(+87%)
Analyst growth 68.5%, PE expands to 12.0
Base Case
$250.53
(+70%)
Market implied 68.5%, PE stable at 10.9
Bear Case
$101.12
(-31%)
Severe decline -20.0%, PE contracts to 9.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.4 to 7.0
Stabilization Target:
$161.21
(+9.3%)
PE Expansion Potential:
+9.3%
Share & Embed Analysis
Last updated: August 03, 2026 12:15 AM ET
Data refreshes hourly during market hours. Next update: 1:15 AM
Data refreshes hourly during market hours. Next update: 1:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Frank E Jaumot
BUY
150 shares
2026-03-20
Warren Hosseinion
BUY
252 shares
2026-03-19
Kelvin Spears
BUY
10 shares
2026-03-17
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$277 | 52 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$453 | 47 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 46 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$24 | 47 HOLD |
|
CON
Concentra Group Holdings… |
STRONG BUY
8 analysts |
$33 | 61 BUY |
